The future of cancer diagnostics lies in the integration of multi-omics approaches, combining genomics, transcriptomics, proteomics, and metabolomics data to provide a holistic view of cancer. Advances in nanotechnology are also expected to play a significant role, enabling the development of nanoscale devices for early cancer detection and targeted drug delivery. Additionally, the incorporation of wearable technologies and continuous monitoring systems will enhance the ability to detect cancer at its earliest stages.
